{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:27Z","timestamp":1792798767893,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19K09292, 22K08985, 25K12115 to SK"],"award-info":[{"award-number":["19K09292, 22K08985, 25K12115 to SK"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21K08426 to AO"],"award-info":[{"award-number":["21K08426 to AO"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutations are significant drivers in various cancers, and existing drug discovery attempts targeting these mutations have largely been unsuccessful, emphasizing the need for more effective therapies. In this study, the screening library, which contains 1,374 chemical compounds, identified nintedanib, a VEGFR inhibitor, as exerting a potent and selective antiproliferative effect against\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant cells, surpassing other VEGFR inhibitors. Nintedanib effectively suppressed tumor growth in xenografted mice with\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutations and significantly inhibited phosphorylated VEGFR2 levels and its downstream signaling molecules pAKT and pERK in\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant cells, suggesting that VEGFR2 inhibition affects the oncogenic AKT\/ERK pathway. Moreover, in VEGFR2-knockout cells, inhibition of SOS1 protein reduced KRAS-GTP activity, which decreased the phosphorylation of ERK, AKT, and DRP1, thereby inducing apoptosis. Remarkably,\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>G12D<\/jats:sup>\n                    overexpression augmented VEGFR2 expression, establishing a positive feedback loop between\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutations and VEGFR2 signaling within the ERK pathway. Immunohistochemical analyses of pancreatic cancer tissues revealed high VEGFR2 expression in 83% (67\/80) of samples, significantly exceeding the levels observed in normal pancreatic tissues. These results underscore VEGFR2 as a promising molecular target and propose a novel therapeutic avenue for\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09015-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:23:13Z","timestamp":1782235393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib inhibits the VEGFR\u2013ERK signaling pathway in human KRAS-mutated cancer cells"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2165-7565","authenticated-orcid":false,"given":"Sivasundaram","family":"Karnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2921","authenticated-orcid":false,"given":"Akinobu","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-7557","authenticated-orcid":false,"given":"Muhammad Nazmul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nushrat","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Towhid Ahmed","family":"Shihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-8927","authenticated-orcid":false,"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam","family":"Quang Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Riku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-8935","authenticated-orcid":false,"given":"Md","family":"Wahiduzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Lutfur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Inaguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-4905","authenticated-orcid":false,"given":"Hiroyuki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"9015_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cancers17050785","volume":"17","author":"P Uniyal","year":"2025","unstructured":"Uniyal P, Kashyap VK, Behl T, Parashar D, Rawat R. KRAS mutations in cancer: understanding signaling pathways to immune regulation and the potential of immunotherapy. Cancers. 2025;17:785.","journal-title":"Cancers"},{"key":"9015_CR2","doi-asserted-by":"publisher","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","volume":"8","author":"C Norton","year":"2025","unstructured":"Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw Open. 2025;8:e2453588.","journal-title":"JAMA Netw Open"},{"key":"9015_CR3","first-page":"318","volume":"63","author":"CL Wolfgang","year":"2013","unstructured":"Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318\u201348.","journal-title":"CA Cancer J Clin"},{"key":"9015_CR4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nrc949","volume":"2","author":"N Bardeesy","year":"2002","unstructured":"Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897\u2013909.","journal-title":"Nat Rev Cancer"},{"key":"9015_CR5","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.22.02770","volume":"41","author":"MJ Moore","year":"2023","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2023;41:4714\u201320.","journal-title":"J Clin Oncol"},{"key":"9015_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, O\u2019Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757\u201365.","journal-title":"N Engl J Med"},{"key":"9015_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023\u201334.","journal-title":"N Engl J Med"},{"key":"9015_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2353\/jmoldx.2008.080105","volume":"10","author":"GJ Riely","year":"2008","unstructured":"Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008;10:493\u20135.","journal-title":"J Mol Diagn"},{"key":"9015_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","volume":"5","author":"M Reck","year":"2010","unstructured":"Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010;5:1616\u201322.","journal-title":"J Thorac Oncol"},{"key":"9015_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"9015_CR11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","volume":"40","author":"SI Ou","year":"2022","unstructured":"Ou SI, Janne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, et al. First-in-human phase I\/IB dose-finding study of Adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40:2530\u20138.","journal-title":"J Clin Oncol"},{"key":"9015_CR12","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","volume":"13","author":"E Massarelli","year":"2007","unstructured":"Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13:2890\u20136.","journal-title":"Clin Cancer Res"},{"key":"9015_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"9015_CR14","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","volume":"70","author":"M Janakiraman","year":"2010","unstructured":"Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010;70:5901\u201311.","journal-title":"Cancer Res"},{"key":"9015_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455.","journal-title":"Signal Transduct Target Ther"},{"key":"9015_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.","journal-title":"Signal Transduct Target Ther"},{"key":"9015_CR17","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.3390\/cancers16213676","volume":"16","author":"TR Peng","year":"2024","unstructured":"Peng TR, Wu TW, Yi TY, Wu AJ. Comparative efficacy of Adagrasib and Sotorasib in KRAS G12C-mutant NSCLC: insights from pivotal trials. Cancers. 2024;16:3676.","journal-title":"Cancers"},{"key":"9015_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","volume":"9","author":"S Casacuberta-Serra","year":"2024","unstructured":"Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Signal Transduct Target Ther. 2024;9:205.","journal-title":"Signal Transduct Target Ther"},{"key":"9015_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"9015_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14796694.5.1.105","volume":"5","author":"MP Quinlan","year":"2009","unstructured":"Quinlan MP, Settleman J. Isoform-specific Ras functions in development and cancer. Future Oncol. 2009;5:105\u201316.","journal-title":"Future Oncol"},{"key":"9015_CR21","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.aam7622","volume":"355","author":"B Papke","year":"2017","unstructured":"Papke B, Der CJ. Drugging RAS: know the enemy. Science. 2017;355:1158\u201363.","journal-title":"Science"},{"key":"9015_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"9015_CR23","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1042\/BST20200506","volume":"48","author":"S Singh","year":"2020","unstructured":"Singh S, Smith MJ. RAS GTPase signalling to alternative effector pathways. Biochem Soc Trans. 2020;48:2241\u201352.","journal-title":"Biochem Soc Trans"},{"key":"9015_CR24","doi-asserted-by":"publisher","first-page":"a031534","DOI":"10.1101\/cshperspect.a031534","volume":"9","author":"P Bandaru","year":"2019","unstructured":"Bandaru P, Kondo Y, Kuriyan J. The interdependent activation of son-of-sevenless and Ras. Cold Spring Harb Perspect Med. 2019;9:a031534.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"9015_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0092-8674(00)00115-X","volume":"103","author":"D Bar-Sagi","year":"2000","unstructured":"Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227\u201338.","journal-title":"Cell"},{"key":"9015_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115828","volume":"261","author":"T Chen","year":"2023","unstructured":"Chen T, Tang X, Wang Z, Feng F, Xu C, Zhao Q, et al. Inhibition of son of sevenless homologue 1 (SOS1): promising therapeutic treatment for KRAS-mutant cancers. Eur J Med Chem. 2023;261:115828.","journal-title":"Eur J Med Chem"},{"key":"9015_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"9015_CR28","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","volume":"21","author":"F McCormick","year":"2015","unstructured":"McCormick F. KRAS as a therapeutic target. Clin Cancer Res. 2015;21:1797\u2013801.","journal-title":"Clin Cancer Res"},{"key":"9015_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","volume":"10","author":"Y Song","year":"2023","unstructured":"Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. Genes Dis. 2023;10:76\u201388.","journal-title":"Genes Dis"},{"key":"9015_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9:92.","journal-title":"Signal Transduct Target Ther"},{"key":"9015_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.21037\/tlcr-22-639","volume":"12","author":"M Santarpia","year":"2023","unstructured":"Santarpia M, Ciappina G, Spagnolo CC, Squeri A, Passalacqua MI, Aguilar A, et al. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review. Transl Lung Cancer Res. 2023;12:346\u201368.","journal-title":"Transl Lung Cancer Res"},{"key":"9015_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351:604\u20138.","journal-title":"Science"},{"key":"9015_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54\u201371.","journal-title":"Cancer Discov"},{"key":"9015_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"9015_CR35","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1021\/pr501191a","volume":"14","author":"DE Hammond","year":"2015","unstructured":"Hammond DE, Mageean CJ, Rusilowicz EV, Wickenden JA, Clague MJ, Prior IA. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations. J Proteome Res. 2015;14:1535\u201346.","journal-title":"J Proteome Res"},{"key":"9015_CR36","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.csbj.2020.04.003","volume":"18","author":"S Vatansever","year":"2020","unstructured":"Vatansever S, Erman B, Gumus ZH. Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras. Comput Struct Biotechnol J. 2020;18:1000\u201311.","journal-title":"Comput Struct Biotechnol J"},{"key":"9015_CR37","doi-asserted-by":"publisher","first-page":"e202201670","DOI":"10.26508\/lsa.202201670","volume":"6","author":"C Ternet","year":"2023","unstructured":"Ternet C, Junk P, Sevrin T, Catozzi S, Wahlen E, Heldin J, et al. Analysis of context-specific KRAS-effector (sub)complexes in Caco-2 cells. Life Sci Alliance. 2023;6:e202201670.","journal-title":"Life Sci Alliance"},{"key":"9015_CR38","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41401-020-0381-y","volume":"41","author":"BY Zhou","year":"2020","unstructured":"Zhou BY, Wang WB, Wu XL, Zhang WJ, Zhou GD, Gao Z, et al. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta Pharmacol Sin. 2020;41:1234\u201345.","journal-title":"Acta Pharmacol Sin"},{"key":"9015_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.102817","volume":"94","author":"Q Li","year":"2025","unstructured":"Li Q, Zhou X, Yang Y, Zhang Q, Li Z, Han H, et al. Nintedanib abrogates patient vitreous-induced Akt activation and tube formation of human retinal microvascular endothelial cells. Tissue Cell. 2025;94:102817.","journal-title":"Tissue Cell"},{"key":"9015_CR40","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/cancers17203354","volume":"17","author":"S Boichuk","year":"2025","unstructured":"Boichuk S, Gessel T. Repurposing the tyrosine kinase inhibitors targeting FGFR and VEGFR pathways for cancer therapy: a comprehensive review. Cancers. 2025;17:3354.","journal-title":"Cancers"},{"key":"9015_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2021.04.015","volume":"152","author":"P Schoffski","year":"2021","unstructured":"Schoffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-Sledz M, Brahmi M, et al. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG \u201cANITA. Eur J Cancer. 2021;152:26\u201340.","journal-title":"Eur J Cancer"},{"key":"9015_CR42","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u2013e47.","journal-title":"Am J Respir Crit Care Med"},{"key":"9015_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1086214","volume":"13","author":"S Yan","year":"2023","unstructured":"Yan S, Xue S, Wang T, Gao R, Zeng H, Wang Q, et al. Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity. Front Oncol. 2023;13:1086214.","journal-title":"Front Oncol"},{"key":"9015_CR44","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.7150\/jca.76695","volume":"13","author":"M Dai","year":"2022","unstructured":"Dai M, Chen S, Teng X, Chen K, Cheng W. KRAS as a key oncogene in the clinical precision diagnosis and treatment of pancreatic cancer. J Cancer. 2022;13:3209\u201320.","journal-title":"J Cancer"},{"key":"9015_CR45","first-page":"2105","volume":"16","author":"XH Yuan","year":"2018","unstructured":"Yuan XH, Yang J, Wang XY, Zhang XL, Qin TT, Li K. Association between EGFR\/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma. Oncol Lett. 2018;16:2105\u201312.","journal-title":"Oncol Lett"},{"key":"9015_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2021.03.007","volume":"507","author":"E Grillo","year":"2021","unstructured":"Grillo E, Corsini M, Ravelli C, Zammataro L, Bacci M, Morandi A, et al. Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. Cancer Lett. 2021;507:80\u201388.","journal-title":"Cancer Lett"},{"key":"9015_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303740120","volume":"120","author":"K Hosaka","year":"2023","unstructured":"Hosaka K, Andersson P, Wu J, He X, Du Q, Jing X, et al. KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. Proc Natl Acad Sci USA. 2023;120:e2303740120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9015_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molcel.2015.01.003","volume":"57","author":"MN Serasinghe","year":"2015","unstructured":"Serasinghe MN, Wieder SY, Renault TT, Elkholi R, Asciolla JJ, Yao JL, et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell. 2015;57:521\u201336.","journal-title":"Mol Cell"},{"key":"9015_CR49","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.celrep.2019.07.031","volume":"28","author":"S Nagdas","year":"2019","unstructured":"Nagdas S, Kashatus JA, Nascimento A, Hussain SS, Trainor RE, Pollock SR, et al. Drp1 promotes KRas-driven metabolic changes to drive pancreatic tumor growth. Cell Rep. 2019;28:1845\u201359.e5.","journal-title":"Cell Rep"},{"key":"9015_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.molcel.2015.01.002","volume":"57","author":"JA Kashatus","year":"2015","unstructured":"Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. 2015;57:537\u201351.","journal-title":"Mol Cell"},{"key":"9015_CR51","doi-asserted-by":"publisher","first-page":"45208","DOI":"10.1021\/acsomega.3c06547","volume":"8","author":"A Adhikary","year":"2023","unstructured":"Adhikary A, Mukherjee A, Banerjee R, Nagotu S. DRP1: At the crossroads of dysregulated mitochondrial dynamics and altered cell signaling in cancer cells. ACS Omega. 2023;8:45208\u201323.","journal-title":"ACS Omega"},{"key":"9015_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02218-1","volume":"24","author":"Q Ma","year":"2025","unstructured":"Ma Q, Zhang W, Wu K, Shi L. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol Cancer. 2025;24:14.","journal-title":"Mol Cancer"},{"key":"9015_CR53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2011.145","volume":"22","author":"Y Hu","year":"2012","unstructured":"Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 2012;22:399\u2013412.","journal-title":"Cell Res"},{"key":"9015_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","volume":"8","author":"W Chen","year":"2023","unstructured":"Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther. 2023;8:333.","journal-title":"Signal Transduct Target Ther"},{"key":"9015_CR55","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s43018-021-00326-1","volume":"3","author":"C Falcomata","year":"2022","unstructured":"Falcomata C, Barthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. 2022;3:318\u201336.","journal-title":"Nat Cancer"},{"key":"9015_CR56","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","volume":"15","author":"P Navarro","year":"2016","unstructured":"Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mouron S, et al. Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics. Cell Rep. 2016;15:2705\u201318.","journal-title":"Cell Rep"},{"key":"9015_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110055","volume":"37","author":"R Elias","year":"2021","unstructured":"Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, et al. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Rep. 2021;37:110055.","journal-title":"Cell Rep"},{"key":"9015_CR58","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/nprot.2014.108","volume":"9","author":"A Pavia-Jimenez","year":"2014","unstructured":"Pavia-Jimenez A, Tcheuyap VT, Brugarolas J. Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing. Nat Protoc. 2014;9:1848\u201359.","journal-title":"Nat Protoc"},{"key":"9015_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21559-9","volume":"12","author":"L Chen","year":"2021","unstructured":"Chen L, Park JE, Paa P, Rajakumar PD, Prekop HT, Chew YT, et al. Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins. Nat Commun. 2021;12:1384.","journal-title":"Nat Commun"},{"key":"9015_CR60","doi-asserted-by":"publisher","first-page":"e0294146","DOI":"10.1371\/journal.pone.0294146","volume":"18","author":"MN Hasan","year":"2023","unstructured":"Hasan MN, Hyodo T, Biswas M, Rahman ML, Mihara Y, Karnan S, et al. Flow cytometry-based quantification of genome editing efficiency in human cell lines using the L1CAM gene. PLoS One. 2023;18:e0294146.","journal-title":"PLoS One"},{"key":"9015_CR61","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"9015_CR62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41420-023-01552-5","volume":"9","author":"S Karnan","year":"2023","unstructured":"Karnan S, Ota A, Murakami H, Rahman ML, Wahiduzzaman M, Hasan MN, et al. CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma. Cell Death Discov. 2023;9:257.","journal-title":"Cell Death Discov"},{"key":"9015_CR63","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/cas.13871","volume":"110","author":"M Wahiduzzaman","year":"2019","unstructured":"Wahiduzzaman M, Karnan S, Ota A, Hanamura I, Murakami H, Inoko A, et al. Establishment and characterization of CRISPR\/Cas9-mediated NF2(-\/-) human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. Cancer Sci. 2019;110:180\u201393.","journal-title":"Cancer Sci"},{"key":"9015_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41420-020-00364-1","volume":"6","author":"S Karnan","year":"2020","unstructured":"Karnan S, Ota A, Murakami H, Rahman ML, Hasan MN, Wahiduzzaman M, et al. Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. Cell Death Discov. 2020;6:127.","journal-title":"Cell Death Discov"},{"key":"9015_CR65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41420-021-00446-8","volume":"7","author":"S Karnan","year":"2021","unstructured":"Karnan S, Hanamura I, Ota A, Takasugi S, Nakamura A, Takahashi M, et al. CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia. Cell Death Discov. 2021;7:121.","journal-title":"Cell Death Discov"},{"key":"9015_CR66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41420-024-01814-w","volume":"10","author":"S Karnan","year":"2024","unstructured":"Karnan S, Hanamura I, Ota A, Vu LQ, Uchino K, Horio T, et al. ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells. Cell Death Discov. 2024;10:56.","journal-title":"Cell Death Discov"},{"key":"9015_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08481-y","volume":"17","author":"S Karnan","year":"2026","unstructured":"Karnan S, Ota A, Hasan MN, Murakami H, Rahman ML, Wahiduzzaman M, et al. Targeting fatty acid synthase suppresses tumor development in NF2\/CDKN2A-deficient pleural mesothelioma. Cell Death Dis. 2026;17:287. https:\/\/doi.org\/10.1038\/s41419-026-08481-y. Feb 28.","journal-title":"Cell Death Dis"},{"key":"9015_CR68","doi-asserted-by":"publisher","first-page":"C245","DOI":"10.1152\/ajpcell.00495.2024","volume":"328","author":"N Jahan","year":"2025","unstructured":"Jahan N, Islam S, Sivasundaram K, Ota A, Naito M, Kuroda J, et al. Role of versican in extracellular matrix formation: analysis in 3D culture. Am J Physiol Cell Physiol. 2025;328:C245\u2013C257.","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09015-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:04:42Z","timestamp":1788782682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09015-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9015"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09015-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This publication has no conflicts of interest, and there has been no substantial financial support for this work that could have influenced its outcome. The manuscript has been reviewed and endorsed by all named authors, and no other individuals meet the criteria for authorship but are not listed. All authors have consented to the order in which they are listed in the manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The research conducted adhered to the ethical standards outlined by the Japanese Ministry of Health, Labour, and Welfare. All methods were performed in accordance with the relevant guidelines and regulations. All animal experiments were conducted in accordance with the protocols (approval number-2023-101) approved by the ethical committee of Aichi Medical University and followed established guidelines. Human tissues were obtained from a commercial provider, which obtained informed consent from all donors prior to tissue collection.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"780"}}